CD38 expression
|
Multiple Myeloma
|
CD38 expression
|
Multiple Myeloma
|
daratumumab Sensitive: B - Late Trials
|
daratumumab Sensitive: B - Late Trials
|
CD38 expression
|
Lymphoma
|
CD38 expression
|
Lymphoma
|
rituximab + NKTR-255 Sensitive: C3 – Early Trials
|
rituximab + NKTR-255 Sensitive: C3 – Early Trials
|
CD38 expression
|
Waldenstrom Macroglobulinemia
|
CD38 expression
|
Waldenstrom Macroglobulinemia
|
daratumumab Sensitive: C3 – Early Trials
|
daratumumab Sensitive: C3 – Early Trials
|
CD38 expression
|
Lymphoma
|
CD38 expression
|
Lymphoma
|
daratumumab + NKTR-255 Sensitive: C3 – Early Trials
|
daratumumab + NKTR-255 Sensitive: C3 – Early Trials
|
CD38 expression
|
Multiple Myeloma
|
CD38 expression
|
Multiple Myeloma
|
BHV-1100 Sensitive: C3 – Early Trials
|
BHV-1100 Sensitive: C3 – Early Trials
|
CD38 expression
|
Multiple Myeloma
|
CD38 expression
|
Multiple Myeloma
|
STI-6129 Sensitive: D – Preclinical
|
STI-6129 Sensitive: D – Preclinical
|
CD38 expression
|
Multiple Myeloma
|
CD38 expression
|
Multiple Myeloma
|
SAR442257 Sensitive: D – Preclinical
|
SAR442257 Sensitive: D – Preclinical
|
CD38 expression
|
Multiple Myeloma
|
CD38 expression
|
Multiple Myeloma
|
SAR442085 Sensitive: D – Preclinical
|
SAR442085 Sensitive: D – Preclinical
|
CD38 expression
|
Multiple Myeloma
|
CD38 expression
|
Multiple Myeloma
|
TAK-079 Sensitive: D – Preclinical
|
TAK-079 Sensitive: D – Preclinical
|
CD38 expression
|
Multiple Myeloma
|
CD38 expression
|
Multiple Myeloma
|
ISB 1342 Sensitive: D – Preclinical
|
ISB 1342 Sensitive: D – Preclinical
|
CD38 expression
|
B Acute Lymphoblastic Leukemia
|
CD38 expression
|
B Acute Lymphoblastic Leukemia
|
isatuximab-irfc Sensitive: D – Preclinical
|
isatuximab-irfc Sensitive: D – Preclinical
|
CD38 expression
|
T Acute Lymphoblastic Leukemia
|
CD38 expression
|
T Acute Lymphoblastic Leukemia
|
isatuximab-irfc Sensitive: D – Preclinical
|
isatuximab-irfc Sensitive: D – Preclinical
|